Therapeutic Target Details
| Target ID: | T31 |
| Target Name: | Galectin-3 |
| Synonyms: | Galectin 3; 35 kDa lectin; Carbohydrate-binding protein 35; CBP 35; Gal-3; Galactose-specific lectin 3; Galactoside-binding protein; GALBP; IgE-binding protein; L-31; Laminin-binding protein; Lectin L-29; Mac-2 antigen; MAC2; LGALS3 |
| GENE: | LGALS3 |
| Action: | inhibitor |
| Class: | Enzyme |
| UniProtKB ID: | P17931 |
| Entry Name: | LEG3_HUMAN |
| Related Drugs: | GR-MD-02; Belapectin |
| Mechanism: | The present study confirmed the roles of Gal3 in hepatic lipid metabolism in both in vitro and in vivo studies and revealed that Gal3 is a secretory protein that promotes hepatic steatosis through the PPARĪ³-CD36-dependent pathway, suggesting that targeting Gal3 may represent a potential therapeutic approach for the treatment of NAFLD and related metabolic disorders. |
| Reference (PMIDs): | 33991615 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0555 | DB01827 | experimental | small molecule | 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide | Target associated | Details |
| R0604 | DB04465 | approved; experimental; investigational | small molecule | Lactose | Target associated | Details |
| R1420 | DB11942 | approved; investigational | small molecule | Selinexor | Therapeutic strategy associated | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B001222 | CHEMBL1162111 | Small molecule | -- | 290.31 | C7H14O8S2 | ACID | Details |
| B001223 | CHEMBL1162112 | Small molecule | -- | 497.51 | C22H28NO8PS | ACID | Details |
| B001224 | CHEMBL1162113 | Small molecule | -- | 407.38 | C15H22NO8PS | ACID | Details |
| B001225 | CHEMBL1162114 | Small molecule | -- | 391.38 | C15H22NO7PS | ACID | Details |
| B001226 | CHEMBL1162115 | Small molecule | -- | 407.47 | C15H21NO8S2 | ACID | Details |
| B002141 | CHEMBL1233058 | Small molecule | GALACTOSE | 180.16 | C6H12O6 | NEUTRAL | Details |
| B002283 | CHEMBL1253187 | Small molecule | -- | 626.65 | C24H34N8O10S | NEUTRAL | Details |
| B002284 | CHEMBL1253188 | Small molecule | -- | 319.34 | C10H17N5O5S | NEUTRAL | Details |
| B002285 | CHEMBL1253217 | Small molecule | -- | 684.72 | C30H40N2O14S | NEUTRAL | Details |
| B002288 | CHEMBL1253726 | Small molecule | -- | 754.82 | C34H42N8O10S | NEUTRAL | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00562 | 35046474 | Sci Rep | Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model. | Details |
| A00775 | 34971904 | Biochem Biophys Res Commun | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. | Details |
| A01665 | 34662732 | Environ Toxicol Pharmacol | Deciphering the toxicological role of Porphyromonas gingivalis derived endotoxins in liver diseases. | Details |
| A02201 | 34462492 | Sci Rep | Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. | Details |
| A02768 | 34250613 | J Clin Periodontol | Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH. | Details |
| A03468 | 33991615 | Cell Signal | Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway. | Details |
| A04016 | 33788377 | Liver Int | Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. | Details |
| A04239 | 33693708 | J Clin Endocrinol Metab | Circulating Galectin-3 Levels Are Not Associated With Nonalcoholic Fatty Liver Disease: A Mendelian Randomization Study. | Details |
| A04450 | 33612037 | Expert Rev Clin Pharmacol | Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. | Details |
| A05525 | 33218405 | Taiwan J Obstet Gynecol | Elevated serum levels of galectin-3 binding protein are associated with insulin resistance in non-diabetic women after menopause. | Details |
| A05574 | 33203036 | Int J Mol Sci | ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. | Details |
| A08371 | 32139740 | Sci Rep | Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation. | Details |
| A09074 | 31883514 | BMC Gastroenterol | Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. | Details |
| A09087 | 31881201 | Exp Mol Pathol | Alpha-syntrophin deficiency protects against non-alcoholic steatohepatitis associated increase of macrophages, CD8+ T-cells and galectin-3 in the liver. | Details |
| A09265 | 31812510 | Gastroenterology | Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. | Details |
| A10434 | 31337151 | Int J Mol Sci | The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. | Details |
| A10589 | 31279739 | Metabolism | Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | Details |
| A12898 | 30235807 | Diseases | Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. | Details |
| A13939 | 29679552 | Clin Biochem | Serum retinol binding protein 4 and galectin-3 binding protein as novel markers for postmenopausal nonalcoholic fatty liver disease. | Details |